ProShares Ultra Nasdaq Biotechnology (BIB)

Add to Watchlists
Create an Alert
90.88 +0.16  +0.18% NASDAQ Jul 2, 8:00PM Delayed 2m USD
View Full Chart
BIB Price Chart

BIB Description

ProShares Ultra Nasdaq Biotechnology is a long-short equity fund managed by ProShares that tracks the NASDAQ Biotechnology TR USD index and has 902.61M USD assets under management. It has an forecasted dividend yield of 0.22%, a forecasted PE ratio of 26.61, and a forecasted price to book value of 6.676. The fund has a net expense ratio of 0.95%, turns over its positions 26.00% per year, and is traded on the NASDAQ.

BIB Key Info

Expense Ratio (1-9-15) 0.95%
Assets Under Management (6-30-15) 902.61M
30-Day Average Volume (7-2-15) 666034.7
Net Asset Value (7-1-15) 90.71
Discount or Premium to NAV (7-1-15) 0.01%
Turnover Ratio (5-31-14) 26.00%

BIB Asset Allocation

Type % Net % Long % Short
Cash -96.32% 30.05% 126.4%
Stock 158.3% 162.2% 3.90%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 38.03% 38.03% 0.00%
As of March 31, 2015

BIB Region Exposure

Americas 96.04%
North America 96.04%
Latin America 0.00%
Greater Europe 3.92%
United Kingdom 1.87%
Europe Developed 2.00%
Europe Emerging 0.00%
Africa/Middle East 0.05%
Greater Asia 0.04%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.04%
Market Classification
% Developed Markets 99.96%
% Emerging Markets 0.04%
As of March 31, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

BIB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 0.00%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of March 31, 2015

BIB Stock Market Capitalization

Giant --
Large --
Medium --
Small --
Micro --
As of March 31, 2015
View More Holdings

BIB Top 10 Holdings

Name % Weight Price % Chg
Nasdaq Biotechnology Index Swap Credit Suisse International 60.69% -- --
Ishares Biotech (Ibb) Swap Bank Of America, Na 17.41% -- --
Ishares Biotech (Ibb) Swap Deutsche Bank Ag 17.38% -- --
Nasdaq Biotechnology Index Swap Bank Of America, Na 9.25% -- --
Nasdaq Biotechnology Index Swap Ubs Ag 7.98% -- --
Biogen Inc 5.67% 404.28 -0.28%
Amgen Inc 5.58% 153.26 -1.12%
Celgene Corp 5.22% 119.52 +1.10%
Gilead Sciences Inc 5.21% 115.04 -0.84%
Nasdaq Biotechnology Index Swap Citibank, N.A. 4.62% -- --
As of March 31, 2015
Advertisement

BIB Basic Info

Style
Equity Style Large Cap/Growth
Broad Asset Class Alternative
Broad Category Alternative
Prospectus Objective Specialty - Health
Fund Owner Firm Name ProShares
Benchmark Index
NASDAQ Biotechnology TR USD 200.0%

BIB Manager Info

Name Tenure
Charles Lowery 1.66 yrs
Michael Neches 1.66 yrs

BIB Risk Info

Beta 1.738
Max Drawdown (All) 41.44%
Historical Sharpe (10y) --
Historical Sortino (All) 3.524
30-Day Rolling Volatility 37.92%
Daily Value at Risk (VaR) 1% (All) 7.80%
Monthly Value at Risk (VaR) 1% (All) 30.83%

BIB Fundamentals

Dividend Yield TTM (7-2-15) 0.00%
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield 0.22%
Forecasted PE Ratio 26.61
Forecasted Price to Sales Ratio 6.709
Forecasted Price to Book Ratio 6.676
Number of Holdings 173
As of March 31, 2015

BIB Growth Estimates

Forecasted 5 Yr Earnings Growth 14.01%
Forecasted Book Value Growth 16.24%
Forecasted Cash Flow Growth 32.74%
Forecasted Earnings Growth 37.19%
Forecasted Revenue Growth 18.11%
As of March 31, 2015

BIB Performance

  Returns Total Returns
1M 3.60% 3.60%
3M 17.42% 17.42%
6M 42.20% 42.20%
1Y 84.42% 84.42%
3Y 562.4% 562.4%
5Y 1683% 1708%
As of July 1, 2015

BIB Net Flows

1M -15.72M
3M 185.19M
6M 288.91M
YTD 197.40M
1Y 243.34M
3Y 461.08M
5Y 479.34M
As of May 31, 2015

BIB Attributes

Key Dates
Inception Date 4/6/2010
Last Annual Report Date 5/31/2014
Last Prospectus Date 1/9/2015
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund Yes
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 7-Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.